| Menopausal syndrome

Climara Pro vs Lynkuet

Side-by-side clinical, coverage, and cost comparison for menopausal syndrome.

Deep comparison between: Climara Pro vs Lynkuet with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsLynkuet has a higher rate of injection site reactions vs Climara Pro based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Lynkuet but not Climara Pro, including UnitedHealthcare

Category

Climara Pro

Lynkuet

At A Glance

RouteTransdermal patch

FrequencyWeekly

ClassEstrogen/progestogen combination

RouteOral

FrequencyDaily

ClassNK1/NK3 receptor antagonist

Indications

Menopausal syndrome
Osteoporosis, Postmenopausal

Menopausal syndrome

Dosing

Menopausal syndrome, Osteoporosis, Postmenopausal 0.045 mg estradiol/0.015 mg levonorgestrel per day applied transdermally once weekly; for vasomotor symptoms, attempts to discontinue should be made at 3 to 6 month intervals.

Menopausal syndrome 120 mg (two 60 mg capsules) orally once daily at bedtime, with or without food; swallow capsules whole.

Contraindications

Undiagnosed abnormal genital bleeding
Breast cancer or history of breast cancer
Estrogen-dependent neoplasia
Active DVT, PE, or a history of these conditions
Active arterial thromboembolic disease (e.g., stroke or MI), or a history of these conditions
Known anaphylactic reaction, angioedema, or hypersensitivity to Climara Pro
Hepatic impairment or disease
Protein C, protein S, or antithrombin deficiency, or other thrombophilic disorders

Pregnancy (exposure may cause pregnancy loss or stillbirth)

Drug Interactions

1699View drug interactions

360View drug interactions

Adverse Reactions

Most common (>3%) Application site reaction, vaginal bleeding, breast pain, upper respiratory infection, back pain, depression, headache, pain, flu syndrome, abdominal pain, arthralgia, edema, flatulence, hypertension, bronchitis, sinusitis, urinary tract infection

Serious Cardiovascular disorders, malignant neoplasms

Postmarketing Changes in bleeding patterns, abdominal distension, abdominal pain, nausea, alopecia, night sweats, pruritus, rash, hot flush, dizziness, headache, insomnia, application site reaction, weight increased, anaphylactic reaction

Most common (>=2%) headache, fatigue, dizziness, somnolence, abdominal pain, rash, diarrhea, muscle spasms

Serious CNS depressant effect and daytime impairment, hepatic transaminase elevations

Pharmacology

Estrogen/progestogen combination; estradiol binds nuclear estrogen receptors in estrogen-responsive tissues to reduce elevated postmenopausal gonadotropin levels, while levonorgestrel inhibits gonadotropin production and counteracts the proliferative effects of estrogen on the endometrium.

Elinzanetant is an NK1 and NK3 receptor antagonist that inhibits Substance P and Neurokinin B through antagonism of NK1 and NK3 receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons, modulating neuronal activity in thermoregulation associated with hot flashes.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Climara Pro